Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MRG003 in EGFR-positive unresectable locally advanced or metastatic biliary adenocarcinoma after failure of standard therapy
CTR20202063Phase 2Terminated
- Sponsor
- Hangzhou Miracogen
- Start
- May 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin in biliary adenocarcinoma, sponsored by Hangzhou Miracogen. Started May 2021; status: terminated.
02
Drugs
becotatug vedotin
03
Conditions
biliary adenocarcinoma
Beyond the preview
Go deeper on CTR20202063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202063.